The Ministry of Health has identified and prioritized Clinical Extremely Vulnerable (CEV) populations to book appointments to receive COVID-19 vaccinations starting March 29, 2021.
All COVID-19 vaccines approved by health Canada for use in Canada, including the AstraZeneca/COVISHIELD vaccine are considered to be very safe products. A normal part of any vaccine rollout is careful monitoring of serious side effects or adverse events that may be associated with its use.
The shortage of tobramycin 0.3% ophthalmic ointment X 3.5 gram tubes has resolved and NH pharmacy now has access to an adequate ongoing supply.
Sodium phosphate 3 mmol/mL injection is currently available in limited quantities only. NH has approximately 3 to 4 weeks of supply between current pharmacy stock and stock available in patient care areas.
Anticipated Availability: early May 2021
The shortage of metoclopramide 5 mg/mL X 2 mL injectable has resolved and NH pharmacy now has access to an adequate ongoing supply.
The shortage of erythromycin 5 mg/g ophthalmic ointment X 1 gram tubes has resolved and NH pharmacy now has access to an adequate ongoing supply.